Indication, study type, substance, and year matrix
Scan where the indexed psilocybin and psilocin literature is dense, sparse, clinical, preclinical, review-driven, or emerging.
Research findings and interpretation
The psilocybin depression evidence guide compares eight selected randomized reports by population, comparator, sample, primary endpoint and follow-up, including positive and inconclusive 2026 findings. It separates published results from sponsor announcements.
Compare the alcohol use disorder evidence or use the research-reading checklist to interpret study designs, endpoints and uncertainty.
This map counts classified records. The guide interprets selected reports; neither is a complete systematic review. For planned and ongoing studies use the depression trial collection.
4,724 evidence cells
Open analytics JSONInterpret and reuse the evidence map
Cell counts describe indexed records, not independent trials, effect sizes or certainty of evidence. A topic can include preclinical work, protocols, reviews and multiple reports from related studies. Verify the source, publication status and study design before using a cell for evidence synthesis.
Inspect the research-year and study-type tables, reproduce your selection with the dataset download and citation guide, and review the classification and correction methods. For registry-specific discovery use the clinical-trial tracker and depression trial collection.
Compare selected primary findings
Move from record counts to study findings with source-linked comparisons of populations, primary endpoints and limitations.
- Psilocybin depression research: findings and limitations
- Psilocybin alcohol use disorder research: findings and limitations
- Psilocybin cancer-related anxiety research: findings and limitations
- Psilocybin smoking cessation research: findings and limitations
These are selected educational comparisons, not exhaustive systematic reviews. Use the research reading checklist to evaluate study design and source status.